Alaunos Therapeutics, Inc. Common Stock (TCRT) Stock Price

TCRTStock

$1.60−23.57%52W

Market Cap$4.08M

P/E—

PEG Ratio0.58

Div yield—

Beta-1.00

TCRT Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-55.61%

Price vs S&P 500 (4W)-17.29%

PEG Ratio0.58

VGM Score18.92

Book Value / Share (Quarterly)$0.54

P/TBV (Annual)0.42x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-88.04%

Cash Flow / Share (Quarterly)$-1.36

Price vs S&P 500 (YTD)-63.13%

Net Profit Margin (TTM)-39320.00%

EPS (TTM)$-2.06

10-Day Avg Trading Volume0.02M

EPS Excl Extra (TTM)$-2.06

EPS (Annual)$-2.14

ROI (Annual)-193.96%

Net Profit Margin (5Y Avg)-170837.58%

Cash / Share (Quarterly)$0.15

Revenue Growth QoQ (YoY)-25.00%

ROA (Last FY)-140.80%

Revenue Growth TTM (YoY)-70.00%

EBITD / Share (TTM)$-2.03

ROE (5Y Avg)-242.29%

Operating Margin (TTM)-39980.00%

Cash Flow / Share (Annual)$-1.26

P/B Ratio3.77x

P/B Ratio (Quarterly)5.28x

Net Income / Employee (Annual)$-4,176,000

EV / Revenue (TTM)901.18x

Net Interest Coverage (TTM)-17.29x

ROA (TTM)-123.50%

EPS Incl Extra (Annual)$-2.14

Current Ratio (Annual)2.45x

Quick Ratio (Quarterly)0.59x

3-Month Avg Trading Volume0.01M

52-Week Price Return-23.57%

Revenue / Employee (TTM)$3,000

Tangible BV / Share (Quarterly)$0.06

P/S Ratio (Annual)971.97x

Asset Turnover (Annual)0.00x

52-Week High$4.59

Operating Margin (5Y Avg)-167729.21%

EPS Excl Extra (Annual)$-2.14

CapEx CAGR (5Y)-60.17%

Tangible BV CAGR (5Y)-3.96%

26-Week Price Return-43.68%

Quick Ratio (Annual)1.71x

13-Week Price Return-47.55%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)1.63x

Enterprise Value$4.51M

Asset Turnover (TTM)0.00x

Book Value / Share Growth (5Y)-13.48%

Revenue / Employee (Annual)$5,000

Pretax Margin (Annual)-83520.00%

Cash / Share (Annual)$0.59

3-Month Return Std Dev65.15%

Net Income / Employee (TTM)$-4,109,000

ROE (Last FY)-193.96%

Net Interest Coverage (Annual)-9.09x

EPS Basic Excl Extra (Annual)$-2.14

Receivables Turnover (TTM)3.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-2.06

Receivables Turnover (Annual)1.25x

ROI (TTM)-165.94%

P/S Ratio (TTM)971.97x

Pretax Margin (5Y Avg)-170837.58%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$0.16

Price vs S&P 500 (52W)-42.13%

Year-to-Date Return-50.31%

5-Day Price Return-6.69%

EPS Normalized (Annual)$-2.14

ROA (5Y Avg)-175.40%

Net Profit Margin (Annual)-83520.00%

Month-to-Date Return-14.63%

Cash Flow / Share (TTM)$-0.14

EBITD / Share (Annual)$-2.16

Operating Margin (Annual)-84500.00%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-228.39%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-2.06

P/TBV (Quarterly)1.15x

P/B Ratio (Annual)3.35x

Pretax Margin (TTM)-39320.00%

Book Value / Share (Annual)$0.92

Price vs S&P 500 (13W)-49.50%

Beta-1.00x

Revenue / Share (TTM)$0.00

ROE (TTM)-165.94%

52-Week Low$1.55

vGradeF

gGradeF

mGradeD

vgmGradeF

TCRT Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q4 2023	Apr 1, 2024	-$4.50	-$17.09	-279.87%(-$12.59)
Q3 2023	Nov 14, 2023	-$5.25	-$4.41	+16.00%(+$0.84)
Q2 2023	Aug 14, 2023	-$6.75	-$6.00	+11.11%(+$0.75)
Q1 2023	May 10, 2023	-$6.60	-$6.00	+9.09%(+$0.60)

TCRT Analyst Recommendations

Dec 2024

Jan 2025

Feb 2025

Mar 2025

2.17

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
TCRTAlaunos Therapeutics, Inc. Common Stock	F	F	D	$1.60
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About Alaunos Therapeutics, Inc. Common Stock

Alaunos Therapeutics is a preclinical-stage biopharmaceutical company developing small-molecule oral therapies for obesity and metabolic disorders. Its lead program, ALN1001, aims to differentiate itself from GLP-1 receptor agonists by preserving lean muscle mass while treating obesity. The company is evaluating the compound's effects on lipid metabolism and gene expression to establish a competitive profile in the obesity treatment market.